Los Angeles Capital Management
CRSP icon

Los Angeles Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Los Angeles Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.8K Buy
773
+60
+8% +$3.17K ﹤0.01% 1559
2025
Q4 		$43.6K Buy
+713
New +$42.7K ﹤0.01% 1647
2021
Q3 		– Sell
-1,277
Closed -$207K – 1494
2021
Q2 		$207K Buy
+1,277
New +$155K ﹤0.01% 1489

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Los Angeles Capital Management's CRSP Position: Q1 2026 in Review

Los Angeles Capital Management increased its CRISPR Therapeutics (CRSP) stake by 8.4% in Q1 2026, buying an estimated $3.17K and bringing the position to 773 shares worth $36.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1559.

Los Angeles Capital Management first reported a position in CRSP in Q2 2021 and has held it in 3 quarters since. The position peaked at $207K in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Los Angeles Capital Management held 773 shares of CRISPR Therapeutics worth $36.8K as of Q1 2026.
  • Los Angeles Capital Management bought 60 CRISPR Therapeutics shares in Q1 2026, an estimated $3.17K.
  • CRISPR Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1559 holding.
  • Los Angeles Capital Management first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • Los Angeles Capital Management's CRISPR Therapeutics position peaked at $207K in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.